{"denoms":[{"counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"60"}],"units":"Participants"}],"groups":[{"description":"CONDITIONING REGIMEN: Patients receive fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO","id":"BG000","title":"Dose Level 1 (No Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"BG001","title":"Dose Level 2 (0.025 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"BG002","title":"Dose Level 3 (0.050 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"BG003","title":"Dose Level 4 (0.10 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"BG004","title":"Dose Level 5 (0.20 mg/kg/Day Campath)"},{"description":"CONDITIONING REGIMEN: Patients receive Alemtuzumab (Campath) on days -8 to -5 as well as fludarabine phosphate IV on days -4 to -2. Patients also undergo low-dose TBI on day 0.\n\nHSCT: Patients undergo allogeneic peripheral blood stem cell transplantation on day 0.\n\nIMMUNOSUPPRESSION: Patients receive CSP IV or PO BID on days -3 to 180 with taper to day 365 and MMF PO TID on days 0-100, with taper to day 156.\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic HSCT\n\nperipheral blood stem cell transplantation: Undergo allogeneic peripheral blood stem cell transplantation\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given IV or PO\n\nalemtuzumab: Given IV","id":"BG005","title":"Dose Level 6 (0.40 mg/kg/Day Campath)"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG006","value":"1"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG006","value":"52"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG006","value":"7"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"13","upperLimit":"72","value":"56.7"},{"groupId":"BG006","lowerLimit":"13","upperLimit":"72","value":"56.7"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG006","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG006","value":"45"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG006","value":"60"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"No subjects were enrolled onto groups beyond Dose level 1 because the dose escalation was not triggered over the course of the study."}